1. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia
by Farhad Ravandi, Susan O'Brien, Deborah Thomas, Stefan Faderl, Dan Jones, Rebecca Garris, Samuel Dara, Jeffrey Jorgensen, Partow Kebriaei, Richard Champlin, Gautam Borthakur, Jan Burger, Alessandra Ferrajoli, Guillermo Garcia-Manero, William Wierda, Jorge Cortes, and Hagop Kantarjian
Blood
Volume 116(12):
September 23, 2010
©2010 by American Society of Hematology

2. Levels of residual disease after 1 cycle of protocol therapy in CR
Levels of residual disease after 1 cycle of protocol therapy in CR. MRD after 1 cycle at CR by (A) BCR-ABL/ABL percentage and (B) flow cytometry.
Levels of residual disease after 1 cycle of protocol therapy in CR. MRD after 1 cycle at CR by (A) BCR-ABL/ABL percentage and (B) flow cytometry.
Farhad Ravandi et al. Blood 2010;116:
©2010 by American Society of Hematology

3. MRD status by PCR and by flow cytometry with follow-up.
MRD status by PCR and by flow cytometry with follow-up. (A) MRD by time from therapy according to BCR-ABL/ABL percentage. The line connects the median values of the patients at the stated time points. Several patients at different time intervals had overlapping values. In 1 patient, BCR-ABL was undetectable at presentation by RT-qPCR and was detected by fluorescence in situ hybridization. (B) MRD by time from therapy according to multiparameter flow cytometry.
Farhad Ravandi et al. Blood 2010;116:
©2010 by American Society of Hematology

4. Event-free survival, CR duration, DFS, and overall survival of the patients.
Event-free survival, CR duration, DFS, and overall survival of the patients. (A) Event-free survival, (B) CR duration, (C) DFS, and (D) overall survival. Numbers of patients at risk are indicated on the horizontal axis.
Farhad Ravandi et al. Blood 2010;116:
©2010 by American Society of Hematology

5. CR duration and overall survival by age and transplant status.
CR duration and overall survival by age and transplant status. (A) CR duration, excluding patients who underwent allogeneic stem cell transplantation in first CR. (B) Overall survival, excluding patients who received transplants in first CR. (C) CR duration by age. (D) Overall survival by age. Numbers of patients at risk are indicated on the horizontal axis.
Farhad Ravandi et al. Blood 2010;116:
©2010 by American Society of Hematology